Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Windward Bio Lists on Nasdaq, Shares Up 68% on Debut


      News provided by

      Pivotal bioVenture Partners China

      Nov 16, 2026, 08:27 ET

      Share this article

      Share this article


      Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding

      SHANGHAI, Nov. 16, 2026 /PRNewswire/ -- Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company and a portfolio company of Pivotal bioVenture Partners China, began trading on the Nasdaq Global Select Market on Nov. 13, 2026. The company priced its initial public offering at $17.00 per share and sold approximately 10.29 million ordinary shares, raising $225 million in gross proceeds, including a $50 million concurrent private placement from Sanofi. Windward closed its first day of trading with a market capitalization of approximately $1.69 billion.

      Windward was founded in 2024 by serial entrepreneur Luca Santarelli, M.D., and his team, whose prior companies VectivBio and Therachon were both acquired. Since inception, the company has raised $365 million, including a $200 million Series A in January 2025 and a $165 million crossover financing in May 2026. Pivotal bioVenture Partners is among the investors that have backed Windward through every financing round since its earliest days, from formation to a Nasdaq listing in under two years.

      Headquartered in Basel, Switzerland, Windward develops ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead program, WIN378, is an ultra-long-acting, fully human monoclonal antibody against thymic stromal lymphopoietin (TSLP) now advancing through POLARIS-1, a Phase 2/3 study in asthma, and SIRIUS, a Phase 2 study in COPD. Designed for twice-yearly dosing, versus the once-every-four-weeks regimen of currently approved agents, WIN378 could meaningfully ease the long-term treatment burden for patients with chronic airway disease. In September 2026, the company reported positive interim Phase 2 data supporting twice-yearly dosing of WIN378 in asthma. Windward's pipeline also includes WIN027, a clinical-stage bispecific antibody targeting TSLP and IL-13 now in Phase 1 development.

      The global rights (excluding Greater China and certain Asian markets) to both of Windward's core programs were licensed from Chinese biopharmaceutical companies. WIN378 (HBM9378/SKB378) came out of a co-development program between Harbour BioMed and Kelun-Biotech, while WIN027 (QX027N) was licensed from Qyuns Therapeutics. Windward is the latest example of China-originated drug candidates reaching global capital markets through license-out deals.

      Windward is a leading case of the NewCo model in the current wave of Chinese biotech going global: a global investment firm leads the spin-out and licensing of a Chinese company's pipeline asset, sets up a new entity overseas, and arms it with international capital and an experienced operating team to run clinical development and commercialization worldwide — typically excluding Greater China. Pivotal bioVenture Partners China's practice has been a consistent investor, participating in the $200 million Series A in January 2025, increasing its position in the $165 million crossover round in May 2026, and remaining a shareholder through the IPO. In less than two years, Windward has completed the full path from "China asset licensing" to "NewCo formation" to "global financing" to "IPO listing," plugging China-originated innovation into the global value chain.

      According to company disclosures, net proceeds from the offering will be used primarily for completing core clinical development of WIN378, including the Phase 2/3 and confirmatory asthma studies and the Phase 2 COPD study; advancing the global Phase 2b COPD trial and the Phase 2 atopic dermatitis trial of WIN027, the latter expected to begin enrollment in the first half of 2027; moving the bispecific program to Investigational New Drug (IND) readiness; and funding working capital and general corporate purposes. After the offering, the pipeline is expected to reach three key data milestones: top-line Phase 2 asthma data for WIN378 (POLARIS-1) in the first half of 2027, Phase 2 COPD data (SIRIUS) in the second half of 2027, and Phase 3 asthma data in the first half of 2029.

      For Pivotal bioVenture Partners, Windward Bio is a prime example of the NewCo model at work — China-originated innovation matched with global capital and world-class execution. From the start, the firm saw WIN378 and WIN027 as potential best-in-class, ultra-long-acting biologics for serious respiratory and dermatologic diseases, and it has backed Luca Santarelli and his team through every financing round since formation. The Nasdaq listing in under two years — putting the value of assets originated by its Chinese partners Harbour BioMed, Kelun-Biotech and Qyuns Therapeutics on the global stage — is a milestone for Pivotal, which plans to keep supporting Windward through its next phase of growth.

      About Windward Bio

      Windward Bio is a clinical-stage biotechnology company with deep drug discovery, development and commercialization experience, focused on transforming the treatment of serious immunological diseases, including respiratory and dermatologic conditions. Its lead program, WIN378, is an ultra-long-acting anti-TSLP monoclonal antibody with best-in-class potential, now in Phase 2/3 clinical trials for asthma. The company's pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLP×IL-13 bispecific antibody with broad therapeutic potential across inflammatory diseases, now in Phase 1. Windward is also building a long-acting bispecific antibody discovery pipeline focused on validated targets in respiratory and dermatologic diseases.

      About Pivotal bioVenture Partners

      Pivotal bioVenture Partners was founded by Hong Kong's Nan Fung Group. Since launching its U.S. operations in 2017 and its China practice in 2018, Pivotal has built broad international reach and global resource-coordination capabilities. The firm seeks out innovative products and technologies worldwide, founding and investing in leading life-science companies in Greater China to meet growing medical needs in global markets — particularly China. Pivotal invests across biopharmaceuticals, medical devices and healthcare services. Its team of seasoned life-science investors and entrepreneurs brings deep industry experience in company creation and venture investment.

      Contact:
      Phone: +86-21-68503033
      Email: [email protected]

      SOURCE Pivotal bioVenture Partners China

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.